From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management
Open accessThe DOI matches its Crossref record; 88 of the 91 references it cites were found in a registry or an index, and 3 are not checked yet; 7 of the 105 sources its claims cite were checked for support.
Abstract
Aims. Despite the very clear association between polycystic ovary syndrome (PCOS) and dysglycemia, few studies have explored the continuum of glycemic alterations leading from minor glucose abnormalities to overt diabetes. The purpose of this review is to trace the natural history of glycemic alteration in women with PCOS.Methods. We performed a literature review without time limit until August 2019. Inclusion criteria were studies addressing the association between impaired glucose tolerance or impaired fasting glucose or type 2 diabetes (T2D) and PCOS with at least an English abstract. The exclusion criteria were no PCOS or impaired glucose tolerance or impaired fasting glucose or T2D as outcome. The outcomes of interest were the onset of impaired glucose tolerance, impaired fasting glucose, T2D, and the progression from impaired glucose tolerance or impaired fasting glucose to T2D.Results. Healthy diet and physical activity are the first-line therapy for PCOS. Treatment with metformin was associated with significant lower 2-hour postload glucose levels and with reduction in fasting glucose when compared to placebo. Thiazolidinediones were more effective in reducing fasting glucose levels compared to placebo. Metformin and pioglitazone treatments showed similar effects on fasting glucose levels. The sodium-glucose cotransporter-2 inhibitor empagliflozin did not show differences in metabolic parameters when compared to metformin. The combination therapy with metformin plus the glucagon-like peptide-1 receptor agonist liraglutide was associated with significant improvements in basal and postload glucose levels compared with only liraglutide. Likewise, a combination therapy with the dipeptidyl peptidase-4 inhibitor saxagliptin and metformin demonstrated superiority versus metformin in fasting glucose and oral glucose tolerance test normalization. Myo-inositol supplementation was associated with lower insulin levels, glucose levels, and insulin resistance when compared with placebo, metformin, or estrogen treatments.Conclusions. The use of insulin-sensitizing agents, such as metformin and inositols, along with lifestyle interventions may improve the metabolic profile in PCOS women.
Verified 2026-10-06 · 3 references not checked yet
Overview
CoChat Summary
TL;DR
This narrative review traces the continuum of glycemic alterations in women with polycystic ovary syndrome (PCOS), from impaired glucose tolerance and impaired fasting glucose to type 2 diabetes, and summarizes lifestyle and pharmacological management options. It concludes that insulin-sensitizing agents such as metformin and inositols, combined with lifestyle intervention, may improve the metabolic profile in PCOS women.
Key findings
- PCOS is associated with a two times increased risk for type 2 diabetes; impaired glucose tolerance prevalence is almost 30% in both adult women and affected adolescents, and insulin action is reduced by 35–40% in lean and obese women with PCOS versus controls.
- Lifestyle modification (diet and physical activity) is the first-line therapy; for overweight women, lowering body mass by 5% can reduce serum insulin and testosterone levels and improve menstrual and reproductive function.
- Metformin was associated with lower fasting glucose versus placebo or no treatment (MD −0.14 mmol/L; 95% CI −0.21 to −0.07) in one Cochrane meta-analysis, though a second meta-analysis of 13 RCTs and 506 subjects found no impact (MD −1.38 mmol/L; 95% CI −3.71, 0.94). In obese adolescents with PCOS and IGT, 8 of 15 normalized their OGTT (2-hour glucose 9.1 ± 0.3 vs. 7.4 ± 0.3 mmol/l; p = 0.005).
- Thiazolidinediones were more effective than placebo in reducing fasting glucose (MD −0.55 mmol/l; 95% CI −1.06 to −0.05; p = 0.031) and showed similar effects to metformin (MD 0.21 mmol/l; 95% CI −0.46 to 0.03; p = 0.089). In one pioglitazone trial, 40% of patients with altered OGTT reverted to normality versus none in the placebo arm.
- Empagliflozin showed no differences in metabolic parameters versus metformin, but favorable effects on body weight (−1.4 kg ± 3.2% vs. 1.2 kg ± 2.3%; p = 0.006) and BMI (p = 0.006). Metformin plus liraglutide improved OGTT at 0 and 120 min versus liraglutide alone (p = 0.015); saxagliptin plus metformin was superior to metformin for fasting glucose and OGTT normalization (p = 0.007), with 91% normalization in the combination arm.
- Myo-inositol improved insulin resistance (HOMA index WMD −1.11; 95% CI −1.39–0.83; p < 0.00001 vs. placebo) and fasting insulin (WMD −3.97; 95% CI −5.76, −2.18; p < 0.00001 vs. placebo), though evidence for an effect on fasting glucose was not strong.
Methods
- Literature review without time limit until August 2019, searching PubMed/Medline, Scopus, Web of Science, Science Direct, Embase, CINAHL, EBSCO, and Google Scholar using MeSH keywords for IGT, IFG, T2D, and PCOS.
- Inclusion criteria: studies addressing the association between IGT, IFG, or T2D and PCOS with at least an English abstract, with focus on available PCOS treatment; exclusion criteria: no PCOS/IGT/IFG/T2D as outcome, conference presentations, and letters to editors.
- All steps independently performed by two researchers, with disagreements resolved by a third researcher; outcomes of interest were onset of IGT, IFG, T2D, and progression from IGT/IFG to T2D.
Limitations
- As stated by the authors: in most PCOS treatment trials the primary objectives are hormonal parameters, ovulatory function, or menstrual irregularities, so studies were underpowered to detect changes in metabolic parameters or diabetes prevention as secondary outcomes; very few studies analyze prediabetes treatment in PCOS and some are retrospective; most have small sample sizes and short observation times (not exceeding 24 weeks for longer studies).
- Evident from the text: the review is narrative rather than systematic, with no formal risk-of-bias assessment or quantitative synthesis; several cited findings are drawn from single small trials or pilot studies (e.g., the 20-subject inositol T2D pilot, the 40-patient empagliflozin RCT), and the authors note that studies analyzing preventive effects from T2D in PCOS women are still lacking.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 1 Not valid · 70 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High intensity aerobic exercise with heart rate >80% improves IR in women with PCOS [38].”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.2. Lifestyle Modifications
What the sources say
- Partly supportedcites [38] Harrison C. L. Stepto N. K. Hutchison S. K. Teede H. J. The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome Clinical Endocrinology 2012 76 3 351 357 10.1111/j.1365-2265.2011.04160.x 2-s2.0-84856987816 21711376 sourceExperimental — accuracy not yet measured
The Exercise Intervention Effects section reports a 16% improvement in insulin resistance among women with PCOS after exercise. The Exercise Intervention section describes a program alternating moderate- and high-intensity sessions, but our copy does not establish that the high-intensity sessions used a heart-rate threshold above 80%; its reference to >80% concerns VO₂max, not heart rate. The study also involved overweight and obese women with PCOS, rather than women with PCOS generally. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Women with PCOS have a higher cardiometabolic risk compared with women without ovarian problems [11].”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 1. Introduction
What the sources say
- Supportedcites [11] Torchen L. C. Cardiometabolic risk in PCOS: more than a reproductive disorder Current Diabetes Reports 2017 17 12 p. 137 10.1007/s11892-017-0956-2 2-s2.0-85034447909 PMC5823507 29128916 source
The Introduction identifies PCOS as a leading risk factor for dysglycemia and type 2 diabetes, and the Cardiovascular Disease Risk Factors section reports increased cardiovascular risk markers in some studies compared with reproductively normal women. This supports the broad claim about cardiometabolic risk; the review distinguishes those risk markers from cardiovascular events, for which increased risk remains uncertain. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The arm with saxagliptin plus metformin demonstrated superiority versus metformin in fasting glucose and OGTT normalization (p = 0.007).”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.7. GLP-1 Receptor Agonist and DPP4 Inhibitors
What the sources say
- Partly supportedcites [69] Tao T. Wu P. Wang Y. Liu W. Comparison of glycemic control and beta-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment BMC Endocrine Disorders 2018 18 1 p. 14 10.1186/s12902-018-0243-5 2-s2.0-85042536089 29482528 PMC5828487 sourceExperimental — accuracy not yet measured
The Results (Table 2; page unavailable) show that fasting glucose and two-hour OGTT glucose improved in both the combination and metformin groups. They do not report OGTT normalization rates or a superiority comparison for these outcomes at p = 0.007; the reported between-group advantage concerns HbA1c (Abstract, Results). (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“When comparing metformin plus OCP to OCP alone, a better outcome on fasting glucose has been shown by Teede et al. [50] in favour of metformin plus OCP (MD 0.38 mmol/l; 95% CI0.22 to 0.54).”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.3. Metformin
What the sources say
- Supportedcites [50] Teede H. Tassone E. C. Piltonen T. Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: a systematic review with meta-analyses Clinical Endocrinology 2019 91 4 479 489 10.1111/cen.14013 2-s2.0-85067675013 31087796 source
Section 3.7 (p. 6) reports a statistically significant improvement in fasting glucose with COCP plus metformin versus COCP alone in adults with PCOS. The reported difference is 0.38 mmol/L (95% CI 0.22 to 0.54), matching the claim. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“After 12 weeks of treatment, the authors observed a significant improvement in the OGTT at 0 and 120 min in the combination therapy arm (p = 0.015).”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.7. GLP-1 Receptor Agonist and DPP4 Inhibitors
What the sources say
- Partly supportedcites [68] Jensterle M. Aleksandra Kravos N. Goričar K. Janez A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial BMC Endocrine Disorders 2017 17 1 p. 5 10.1186/s12902-017-0155-9 2-s2.0-85011277712 28143456 PMC5286837 sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 30 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
56 more claims · 2 with their cited sources checked
Create a free account to see all 96 claims and to verify the 98 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 30
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, hyperinsulinemia is responsible for the increase in the androgen production through both the direct stimulation of insulin receptors and the cross-reaction with Insulin-like Growth Factor-1 (IGF-1) receptors expressed on thecal cells [14].”
From Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? (2023) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“patients treated with placebo had a deterioration of the glucose tolerance measured at the OGTT with respect to the group treated with placebo.”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“13 women with PCOS treated for 6 months with pioglitazone 45 mg per day with 10 women treated with placebo.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“MD: 0.21 mmol/l”
§ From Prediabetes to Type 2 Diabetes Mellitus in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management > 3. Results and Discussion > 3.5. Thiazolidinediones
“95% CI −0.46 to 0.03”
Citations
Cites
1 retracted
Psychological interventions for overweight or obesity
Shaw, K. A., O'Rourke, P., Del Mar, C., & Kenardy, J. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003818.pub2 · Cited by 442
RetractedGlucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Furthermore, it is supposed that the energy imbalance produced by metformin could activate the 5′ adenosine monophosphateactivated protein kinase (AMPK) that would enhance catabolic pathways in order to restore the cellular energetic equilibrium [42].”
BackgroundProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947 · cited 2×
“PCOS is defined by its reproductive features of hyperandrogenism, chronic oligoanovulation, and/or polycystic ovarian morphology [2].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Teede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., Andersen, M., Azziz, R., et al. (2018) · Fertility and Sterility · doi:10.1016/j.fertnstert.2018.05.004 · Cited by 1,325
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
Madiraju, A. K., Erion, D. M., Rahimi, Y., Zhang, X.-M., Braddock, D. T., Albright, R. A., Prigaro, B. J., Wood, J. L., Bhanot, S., MacDonald, M. J., et al. (2014) · Nature · doi:10.1038/nature13270 · Cited by 1,284
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., Laven, J. S., & Legro, R. S. (2015) · Endocrine Reviews · doi:10.1210/er.2015-1018 · Cited by 1,020
Kiddy, D. S., Hamilton‐Fairley, D., Bush, A., Short, F., Anyaoku, V., Reed, M. J., & Franks, S. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb02909.x · Cited by 921 · cited 1×
“Particularly for overweight women with PCOS, lowering body mass by 5% can reduce serum insulin and testosterone levels and improve menstrual and reproductive function [35].”
BackgroundVelazquez, E. M., Mendoza, S., Hamer, T., Sosa, F., & Glueck, C. J. (1994) · Metabolism · doi:10.1016/0026-0495(94)90209-7 · Cited by 865 · cited 2×
“'e first trial assessing a beneficial role of metformin has been published in 1994 by Velazquez and Colleagues [45] who described a significant improvement in systolic blood pressure, insulin sensitivity, androgen, follicle-stimulating hormone (FSH), and SHBG levels after 8 weeks of therapy with metformin 1.5 g per da…”
BackgroundInfluentialA meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome
Boomsma, C. M., Eijkemans, M. J. C., Hughes, E. G., Visser, G. H. A., Fauser, B. C. J. M., & Macklon, N. S. (2006) · Human Reproduction Update · doi:10.1093/humupd/dml036 · Cited by 852
NESTLER, J. E., POWERS, L. P., MATT, D. W., STEINGOLD, K. A., PLYMATE, S. R., RITTMASTER, R. S., CLORE, J. N., & BLACKARD, W. G. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-1-83 · Cited by 815
Cellular Mechanisms for Insulin Resistance in Normal Pregnancy and Gestational Diabetes
Barbour, L. A., McCurdy, C. E., Hernandez, T. L., Kirwan, J. P., Catalano, P. M., & Friedman, J. E. (2007) · Diabetes Care · doi:10.2337/dc07-s202 · Cited by 811
Metformin and the gastrointestinal tract
McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016) · Diabetologia · doi:10.1007/s00125-015-3844-9 · Cited by 733 · cited 1×
“More recently, an action of metformin also in the gut has been proposed, where it has shown to increase glucose uptake and use in the enterocytes and glucagon-like peptide-1 (GLP-1) secretion [43].”
BackgroundTang, T., Lord, J. M., Norman, R. J., Yasmin, E., & Balen, A. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003053.pub5 · Cited by 698
Nestler, J. E., Jakubowicz, D. J., Falcon de Vargas, A., Brik, C., Quintero, N., & Medina, F. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.6.4886 · Cited by 617
Dunaif, A., Xia, J., Book, C. B., Schenker, E., & Tang, Z. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118126 · Cited by 561 · cited 1×
“'ey observed that insulin receptors isolated from fibroblast cultured and skeletal muscle of women with PCOS presented increased insulin-independent autophosphorylation which is associated with reduced receptor activity [24, 25] and can lead to IR.”
BackgroundDay, F. R., Hinds, D. A., Tung, J. Y., Stolk, L., Styrkarsdottir, U., Saxena, R., Bjonnes, A., Broer, L., Dunger, D. B., Halldorsson, B. V., et al. (2015) · Nature Communications · doi:10.1038/ncomms9464 · Cited by 459 · cited 1×
“Genetic analyses showed that metabolic abnormalities such as obesity and IR contribute to the pathogenesis of PCOS [10].”
BackgroundInsulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus
Ovalle, F., & Azziz, R. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03111-4 · Cited by 428 · cited 1×
“Reported prevalence of IR in women with PCOS varies from 44% to 70% [19] mostly because of different methods used to assess it [20].”
MethodLindheim, L., Bashir, M., Münzker, J., Trummer, C., Zachhuber, V., Leber, B., Horvath, A., Pieber, T. R., Gorkiewicz, G., Stadlbauer, V., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0168390 · Cited by 416 · cited 2×
“Alternative mechanisms of the pathogenesis of prediabetes and T2D in subjects with PCOS are muscle mitochondrial dysfunction [28] and the gut microbiome [29].”
Willis, D., Mason, H., Gilling-Smith, C., & Franks, S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550768 · Cited by 371 · cited 1×
“'ey observed that insulin receptors isolated from fibroblast cultured and skeletal muscle of women with PCOS presented increased insulin-independent autophosphorylation which is associated with reduced receptor activity [24, 25] and can lead to IR.”
BackgroundADASHI, E. Y., HSUEH, A. J. W., & YEN, S. S. C. (1981) · Endocrinology · doi:10.1210/endo-108-4-1441 · Cited by 366 · cited 1×
“Indeed, insulin acts as a cogonadotropin to increase luteinizing hormone (LH)-induced androgen synthesis in theca cells [4] and can enhance gonadotropin-releasing hormone (GnRH)-mediated gonadotropin secretion [5].”
BackgroundLong or Highly Irregular Menstrual Cycles as a Marker for Risk of Type 2 Diabetes Mellitus
Solomon, C. G. (2001) · JAMA · doi:10.1001/jama.286.19.2421 · Cited by 362 · cited 1×
“For this reason, PCOS is associated with a two times increased risk for type 2 diabetes (T2D) [15].”
BackgroundScreening for Abnormal Glucose Tolerance in Adolescents with Polycystic Ovary Syndrome
Palmert, M. R., Gordon, C. M., Kartashov, A. I., Legro, R. S., Emans, S. J., & Dunaif, A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8305 · Cited by 354 · cited 1×
“In women with PCOS, dysglycemia typically consists of impaired glucose tolerance [12], its prevalence being of almost 30% in both adult women [13] and affected adolescents [14].”
BackgroundDefects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS)
Dunaif, A., Wu, X., Lee, A., & Diamanti-Kandarakis, E. (2001) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2001.281.2.e392 · Cited by 337 · cited 1×
“However, other abnormalities have been observed also in downstream pathways, such as the serine phosphorylation of the insulin receptor substrates which inhibits its binding with PI3K and prevents the propagation of the signal downstream [26, 27].”
BackgroundCellular mechanisms of insulin resistance in polycystic ovarian syndrome
Ciaraldi, T. P. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.2.577 · Cited by 336
Is PCOS an inflammatory process?
Duleba, A. J., & Dokras, A. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.11.023 · Cited by 327
Qin, J. Z., Pang, L. H., Li, M. J., Fan, X. J., Huang, R. D., & Chen, H. Y. (2013) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-11-56 · Cited by 317
Complications and challenges associated with polycystic ovary syndrome: current perspectives
Palomba, S., Santagni, S., Falbo, A., & La Sala, G. B. (2015) · International Journal of Women's Health · doi:10.2147/ijwh.s70314 · Cited by 287
Corbould, A., Kim, Y.-B., Youngren, J. F., Pender, C., Kahn, B. B., Lee, A., & Dunaif, A. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00361.2004 · Cited by 283 · cited 1×
“However, other abnormalities have been observed also in downstream pathways, such as the serine phosphorylation of the insulin receptor substrates which inhibits its binding with PI3K and prevents the propagation of the signal downstream [26, 27].”
BackgroundArslanian, S. A., Lewy, V., Danadian, K., & Saad, R. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8398 · Cited by 272 · cited 1×
“A trial performed in obese adolescents with PCOS and impaired glucose tolerance [51] evaluated three months of therapy with metformin and showed an improvement in glucose tolerance in this specific population; in fact, 8 out of 15 subjects had a normalization in their oral glucose tolerance test (OGTT) with significan…”
MethodNormal Pregnancy- A State of Insulin Resistance
Sonagra, A. D. (2014) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2014/10068.5081 · Cited by 268
The Effects of a Low-Carbohydrate, Ketogenic Diet on the Polycystic Ovary Syndrome: A Pilot Study
Mavropoulos, J. C., Yancy, W. S., Hepburn, J., & Westman, E. C. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-35 · Cited by 226
Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study
Ding, E. L., Song, Y., Manson, J. E., Rifai, N., Buring, J. E., & Liu, S. (2007) · Diabetologia · doi:10.1007/s00125-007-0785-y · Cited by 208 · cited 1×
“However, hyperandrogenism in PCOS could worsen glucose tolerance by stimulating low-grade inflammation [17, 18].”
BackgroundEffects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
Unfer, V., Carlomagno, G., Dante, G., & Facchinetti, F. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.650660 · Cited by 201
Costello, M. F., Shrestha, B., Eden, J., Johnson, N., & Moran, L. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005552.pub2 · Cited by 197 · cited 1×
“Another Cochrane meta-analysis [49] compared metformin with oral contraceptive pill (OCP) and did not find significant differences for FBG.”
Neven, A., Laven, J., Teede, H., & Boyle, J. (2018) · Seminars in Reproductive Medicine · doi:10.1055/s-0038-1668085 · Cited by 196 · cited 1×
“Obesity and abdominal obesity have a significant impact on psychosocial status, quality of life, hyperandrogenism, IR, lipid profiles, ovulation, menstrual cycle, fertility, risks for T2D, and cardiovascular disease onset [30, 31].”
BackgroundMyo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017) · Endocrine Connections · doi:10.1530/ec-17-0243 · Cited by 188
Lifestyle Modification Programs in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis
Domecq, J. P., Prutsky, G., Mullan, R. J., Hazem, A., Sundaresh, V., Elamin, M. B., Phung, O. J., Wang, A., Hoeger, K., Pasquali, R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2385 · Cited by 184 · cited 1×
“Lifestyle modification is the first-line therapy for women with PCOS [33].”
BackgroundNelson-Degrave, V. L., Wickenheisser, J. K., Hendricks, K. L., Asano, T., Fujishiro, M., Legro, R. S., Kimball, S. R., Strauss, J. F., & McAllister, J. M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0178 · Cited by 167 · cited 1×
“itself, acts synergistically on theca cells, increasing androgen biosynthesis [4, 23].”
BackgroundD’Anna, R., Scilipoti, A., Giordano, D., Caruso, C., Cannata, M. L., Interdonato, M. L., Corrado, F., & Di Benedetto, A. (2013) · Diabetes Care · doi:10.2337/dc12-1371 · Cited by 166
Almenning, I., Rieber-Mohn, A., Lundgren, K. M., Shetelig Løvvik, T., Garnæs, K. K., & Moholdt, T. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138793 · Cited by 155 · cited 1×
“However, both high intensity interval training and strength training improve IR and body composition in women with PCOS [39].”
BackgroundNutritional management in women with polycystic ovary syndrome: A review study.
Faghfoori, Z., Fazelian, S., Shadnoush, M., & Goodarzi, R. (2017) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2017.03.030 · Cited by 153
Facchinetti, F., Bizzarri, M., Benvenga, S., D’Anna, R., Lanzone, A., Soulage, C., Di Renzo, G. C., Hod, M., Cavalli, P., Chiu, T. T., et al. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.09.024 · Cited by 145
Goverde, A. J., van Koert, A. J. B., Eijkemans, M. J., Knauff, E. A. H., Westerveld, H. E., Fauser, B. C. J. M., & Broekmans, F. J. (2008) · Human Reproduction · doi:10.1093/humrep/den433 · Cited by 135
Javed, Z., Papageorgiou, M., Deshmukh, H., Rigby, A. S., Qamar, U., Abbas, J., Khan, A. Y., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.13968 · Cited by 121
The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes
Pintaudi, B., Di Vieste, G., & Bonomo, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/9132052 · Cited by 117
Self-citationPundir, J., Psaroudakis, D., Savnur, P., Bhide, P., Sabatini, L., Teede, H., Coomarasamy, A., & Thangaratinam, S. (2018) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.14754 · Cited by 115
Matarrelli, B., Vitacolonna, E., D’angelo, M., Pavone, G., Mattei, P. A., Liberati, M., & Celentano, C. (2013) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.766691 · Cited by 114
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0252 · Cited by 113 · cited 1×
“In a survey performed by the European Society of Endocrinology (ESE) PCOS Special Interest Group [46] on a group of experts mainly composed of endocrinologists, metformin was indicated as the respondent first choice for the overall treatment of PCOS.”
BackgroundOrtmeyer, H. K., Huang, L. C., Zhang, L., Hansen, B. C., & Larner, J. (1993) · Endocrinology · doi:10.1210/endo.132.2.8425484 · Cited by 113 · cited 1×
“Both myo- and d-chiro-inositol showed insulin mimetic effects in animal models of IR [71].”
Background(2012) · PubMed · Cited by 111
Benelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3204083 · Cited by 100
In vivo conversion of [3H]myoinositol to [3H]chiroinositol in rat tissues.
Pak, Y., Huang, L. C., Lilley, K. J., & Larner, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41870-4 · Cited by 95
Myo-inositol may prevent gestational diabetes in PCOS women
D’Anna, R., Di Benedetto, V., Rizzo, P., Raffone, E., Interdonato, M. L., Corrado, F., & Di Benedetto, A. (2012) · Gynecological Endocrinology · doi:10.3109/09513590.2011.633665 · Cited by 95
Facchinetti, F., Orrù, B., Grandi, G., & Unfer, V. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1540578 · Cited by 94 · cited 1×
“metformin in PCOS women showed no difference in the short-term effect for fasting insulin, HOMA index, testosterone, androstenedione, SHBG, and BMI, further highlighting the absence of side effects in the myoinositol group compared to the metformin one [88].”
ResultJensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
Pasquali, R., Fabbri, R., Venturoli, S., Paradisi, R., Antenucci, D., & Melchionda, N. (1986) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(86)90410-2 · Cited by 92
Giordano, D., Corrado, F., Santamaria, A., Quattrone, S., Pintaudi, B., Di Benedetto, A., & D'Anna, R. (2011) · Menopause · doi:10.1097/gme.0b013e3181e8e1b1 · Cited by 89
Self-citationCree-Green, M., Rahat, H., Newcomer, B. R., Bergman, B. C., Brown, M. S., Coe, G. V., Newnes, L., Garcia-Reyes, Y., Bacon, S., Thurston, J. E., et al. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00192 · Cited by 82
Harrison, C. L., Stepto, N. K., Hutchison, S. K., & Teede, H. J. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04160.x · Cited by 80
Teede, H., Tassone, E. C., Piltonen, T., Malhotra, J., Mol, B. W., Peña, A., Witchel, S. F., Joham, A., McAllister, V., Romualdi, D., et al. (2019) · Clinical Endocrinology · doi:10.1111/cen.14013 · Cited by 79
Vitagliano, A., Saccone, G., Cosmi, E., Visentin, S., Dessole, F., Ambrosini, G., & Berghella, V. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-5005-0 · Cited by 74
Aroda, V. R., Ciaraldi, T. P., Burke, P., Mudaliar, S., Clopton, P., Phillips, S., Chang, R. J., & Henry, R. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1133 · Cited by 71 · cited 1×
“In their study, Aroda and colleagues [65] compared 13 women with PCOS treated for 6 months with pioglitazone 45mg per day with 10 women treated with placebo.”
BackgroundLi, X.-J., Yu, Y.-X., Liu, C.-Q., Zhang, W., Zhang, H.-J., Yan, B., Wang, L.-Y., Yang, S.-Y., & Zhang, S.-H. (2011) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03917.x · Cited by 67
Cardiometabolic Risk in PCOS: More than a Reproductive Disorder
Torchen, L. C. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0956-2 · Cited by 65
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63 · cited 1×
“5 : 1; 5 : 1; 20 : 1; 40 : 1; 80 : 1), the 40 : 1 myo-inositol/d-chiro-inositol has shown to better restore ovulation and improve hormonal levels, basal and postprandial insulin levels, and HOMA index [89].”
BackgroundEffectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis
Zeng, L., & Yang, K. (2018) · Endocrine · doi:10.1007/s12020-017-1442-y · Cited by 59 · cited 4×
“Also, a very recent systematic review and meta-analysis [81] of five RCTs (965 participants) significantly supported the therapy with myo-inositol alone or plus d-chiro-inositol in the prevention of GDM.”
InfluentialJeanes, Y. M., Barr, S., Smith, K., & Hart, K. H. (2009) · Journal of Human Nutrition and Dietetics · doi:10.1111/j.1365-277x.2009.00988.x · Cited by 59 · cited 1×
“Diet advice often requires a reduction in dietary glycemic index in addition to overall calorie reduction to induce weight loss [36].”
BackgroundZhuo, Z., Wang, A., & Yu, H. (2014) · Journal of Diabetes Research · doi:10.1155/2014/381231 · Cited by 55
Celentano, C., Matarrelli, B., Pavone, G., Vitacolonna, E., Mattei, P. A., Berghella, V., & Liberati, M. (2020) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1500545 · Cited by 54
Du, Q., Wang, Y.-J., Yang, S., Wu, B., Han, P., & Zhao, Y.-Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.681636 · Cited by 53 · cited 1×
“'e same group performed another meta-analysis [64] including five trials comparing pioglitazone versus metformin on 258 patients, with fasting glucose levels as an outcome.”
MethodTan, X., Li, S., Chang, Y., Fang, C., Liu, H., Zhang, X., & Wang, Y. (2016) · Clinical and Investigative Medicine · doi:10.25011/cim.v39i4.27091 · Cited by 51
Feng, L., Lin, X.-F., Wan, Z.-H., Hu, D., & Du, Y.-K. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1041906 · Cited by 50
Sharma, S. T., Wickham, E. P., & Nestler, J. E. (2007) · Endocrine Practice · doi:10.4158/ep.13.4.373 · Cited by 49 · cited 1×
“In a retrospective study of 50 patients with PCOS [52], without diabetes at the baseline and treated with metformin, followed up for at least one year and with a mean follow-up of 40.”
BackgroundDu, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0044-6 · Cited by 47 · cited 1×
“[63] performed a meta-analysis evaluating effects of rosiglitazone or pioglitazone versus placebo on metabolic outcomes.”
MethodJensterle, M., Janez, A., Mlinar, B., Marc, J., Prezelj, J., & Pfeifer, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0857 · Cited by 47 · cited 1×
“In fact, metformin has shown to enhance expression of GLUT4 mRNA in the adipose tissue of patients with PCOS [44] (which was found to be significantly lower compared to healthy controls).”
BackgroundPatel, R., & Shah, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1279597 · Cited by 47
d-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review
Galazis, N., Galazi, M., & Atiomo, W. (2011) · Gynecological Endocrinology · doi:10.3109/09513590.2010.538099 · Cited by 46 · cited 2×
“'ree reviews including a total of 62 trials with 5072 women with PCOS evaluated the efficacy of inositol in PCOS [47, 85, 86].”
BackgroundMethodHurd, W. W., Abdel-Rahman, M. Y., Ismail, S. A., Abdellah, M. A., Schmotzer, C. L., & Sood, A. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.07.002 · Cited by 46 · cited 1×
“Reported prevalence of IR in women with PCOS varies from 44% to 70% [19] mostly because of different methods used to assess it [20].”
MethodDietary Therapy in Polycystic Ovary Syndrome
Moran, L., Brinkworth, G., & Norman, R. (2008) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-992928 · Cited by 45
Fraticelli, F., Celentano, C., Zecca, I. A., Di Vieste, G., Pintaudi, B., Liberati, M., Franzago, M., Di Nicola, M., & Vitacolonna, E. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1157-4 · Cited by 39
Self-citationTao, T., Wu, P., Wang, Y., & Liu, W. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0243-5 · Cited by 38 · cited 2×
“Another study [69] performed on premenopausal patients with PCOS and impaired fasting glucose or impaired glucose tolerance randomly assigned patients to three different treatments: metformin extended release 2000mg once daily, saxagliptin 5mg once daily, and the combination of both 5mg saxagliptin and 2000mgmetformin…”
MethodPersistent Apparent Pancreatic β-Cell Defects in Premenarchal PCOS Relatives
Torchen, L. C., Fogel, N. R., Brickman, W. J., Paparodis, R., & Dunaif, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1474 · Cited by 33
Zhao, J., Liu, X., & Zhang, W. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0603-3394 · Cited by 31
Bidhendi Yarandi, R., Behboudi-Gandevani, S., Amiri, M., & Ramezani Tehrani, F. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0453-7 · Cited by 29
Lubin, V., Shojai, R., Darmon, P., & Cosson, E. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.01.005 · Cited by 21
Effects of myo-inositol on glucose variability in women with gestational diabetes.
Pintaudi, B., Vieste, G. D., Corrado, F., Lucisano, G., Giunta, L., D’Anna, R., & Benedetto, A. D. (2018) · PubMed · doi:10.26355/eurrev_201810_16073 · Cited by 15
Self-citation
Research works printed but not linked: 1
- International Diabetes Federation Idf Diabetes Atlas 2017 8 Brussels, Belgium International Diabetes Federation 35914061
Cited by
Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review
Livadas, S., Anagnostis, P. G., Bosdou, J. Κ., Bantouna, D., & Paparodis, R. D. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.5 · Cited by 131
PCOS and nutritional approaches: Differences between lean and obese phenotype
Barrea, L., Frias-Toral, E., Verde, L., Ceriani, F., Cucalón, G., Garcia-Velasquez, E., Moretti, D., Savastano, S., Colao, A., & Muscogiuri, G. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100123 · Cited by 86
Shpakov, A. O. (2021) · Pharmaceuticals · doi:10.3390/ph14010042 · Cited by 91
Role of macrophages in the endocrine system
Rehman, A., Pacher, P., & Haskó, G. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.12.001 · Cited by 71
Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium
Xue, Z., Li, J., Feng, J., Han, H., Zhao, J., Zhang, J., Han, Y., Wu, X., & Zhang, Y. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.788772 · Cited by 71
Metadata
- Authors
- Pani, A., Gironi, I., Di Vieste, G., Mion, E., Bertuzzi, F., & Pintaudi, B.
- Affiliations
- University of Milan (IT)
- Diabetes Consultant, Milan, Italy
- Diabetes Unit, Cantù Hospital, Abbiategrasso, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- Corresponding author
- Pintaudi, Basilio
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2020-06-08
- Volume
- 2020
- Pages
- 1-10
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- PMC
- PMC7298266
- OpenAlex
- W3034163622
- Semantic Scholar
- 7587392706ddd7085ef3c29f2dcc1a4bdb0e0876
- Cited by
- 38
- References
- 91
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 4 · 2023: 9 · 2022: 8 · 2021: 6 · 2020: 3
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- International Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- polycystic ovary syndrome, type 2 diabetes, prediabetes, impaired glucose tolerance, impaired fasting glucose, dysglycemia, metformin, thiazolidinediones, pioglitazone, empagliflozin, liraglutide, saxagliptin, myo-inositol, insulin resistance, lifestyle intervention, physical activity, diet, insulin sensitizers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.